Study S002022

A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01916174
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 50
Start: 2013-08
Primary completion: 2013-11
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2; Healthy
Interventions: DRUG:insulin degludec/liraglutide
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2012-005468-93; OTHER:U1111-1137-3809

Registered primary outcomes

Area under the serum IDeg concentration time curve after single dose [Assessed from 0 to 120 hours]
Maximum observed serum IDeg concentration after single dose [Assessed from 0-120 hours]
Area under the plasma liraglutide concentration time curve after single dose [Assessed from 0-72 hours]
Maximum observed plasma liraglutide concentration after single dose [Assessed from 0-72 hours]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.